- Home
- CPRX vs RXRX Comparison
CPRX vs RXRX Comparison
Compare CPRX & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | RXRX |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CPRX | RXRX |
|---|---|---|
| Price | $23.64 | $3.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $32.50 | $7.20 |
| AVG Volume (30 Days) | 1.1M | ★ 18.5M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | 14.79 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $119,072,803.00 | $74,681,000.00 |
| Revenue This Year | $7.14 | $12.95 |
| Revenue Next Year | $7.68 | $88.63 |
| P/E Ratio | $13.68 | ★ N/A |
| Revenue Growth | 16.39 | ★ 26.92 |
| 52 Week Low | $19.05 | $2.98 |
| 52 Week High | $26.56 | $7.18 |
Technical Indicators
Market Signals| Indicator | CPRX | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 43.48 |
| Support Level | $22.25 | $2.98 |
| Resistance Level | $24.81 | $5.06 |
| Average True Range (ATR) | 0.97 | 0.26 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 52.61 | 59.50 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.